To include your compound in the COVID-19 Resource Center, submit it here.

Scared off Sequenom

Sequenom stock falls on possible fundraising ahead of Down's Syndrome data

Sequenom Inc. (NASDAQ:SQNM) shareholders got cold feet last week after the company said on its earnings call that it will need to raise money this year - and that it will not necessarily wait for data from its SEQureDx Down Syndrome test to do so.

On the week,

Read the full 472 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE